Increased Risk of Preterm Birth in Veterans with PTSD
Largest studies to date demonstrate statistically significant risk of preterm birth among women with active PTSD.
Largest studies to date demonstrate statistically significant risk of preterm birth among women with active PTSD.
In 2019, brexanolone was introduced by Sage Therapeutics as Zulresso, a novel treatment for postpartum depression. The oral version of this novel antidepressant – SAGE 217 or zuranolone – is now finishing up its Phase [...]